GBLX (GB Sciences) EBITDA Margin %: -69.07% (As of Dec. 2024)


What is GB Sciences EBITDA Margin %?

GB Sciences GBLX EBITDA Margin % is -69.07% as of Dec. 2024.

EBITDA Margin % is calculated as EBITDA divided by its Revenue. GB Sciences's EBITDA for the three months ended in Dec. 2024 was $-0.07 Mil. GB Sciences's Revenue for the three months ended in Dec. 2024 was $0.10 Mil. Therefore, GB Sciences's EBITDA margin for the quarter that ended in Dec. 2024 was -69.07%.

GB Sciences  (OTCPK:GBLX) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

GB Sciences EBITDA Margin % Related Terms

GB Sciences EBITDA Margin % Historical Data

* Premium members only.

The historical data trend for GB Sciences's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

GB Sciences EBITDA Margin % Chart

GB Sciences Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
EBITDA Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -309.68 0.00 0.00 0.00 0.00

GB Sciences Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 -69.07

GBLX vs QRON, ENDV, CNBX: EBITDA Margin % Comparison

For the Biotechnology subindustry, GB Sciences's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

GB Sciences EBITDA Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, GB Sciences's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where GB Sciences's EBITDA Margin % falls into.


GB Sciences EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

GB Sciences's EBITDA Margin % for the fiscal year that ended in Mar. 2024 is calculated as

EBITDA Margin %=EBITDA (A: Mar. 2024 )/Revenue (A: Mar. 2024 )
=-1.142/0
= %

GB Sciences's EBITDA Margin % for the quarter that ended in Dec. 2024 is calculated as

EBITDA Margin %=EBITDA (Q: Dec. 2024 )/Revenue (Q: Dec. 2024 )
=-0.067/0.097
=-69.07 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBITDA Margin % →
What does a EBITDA Margin % of -69.07% mean?
GB Sciences (GBLX) has a EBITDA Margin % of -69.07% as of Dec. 2024. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on GB Sciences and its competitors.
Is GB Sciences' EBITDA Margin % too high?
GB Sciences' current EBITDA Margin % is -69.07%.
How does GB Sciences' EBITDA Margin % compare to QRON and ENDV?
GB Sciences' EBITDA Margin % of -69.07% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on GB Sciences and its competitors. GB Sciences's current EBITDA Margin % is -69.07%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GB Sciences stock overvalued right now?
GB Sciences (GBLX) has a current EBITDA Margin % of -69.07%. The current EBITDA Margin % is -69.07%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For GB Sciences (GBLX), the current EBITDA Margin % is -69.07% as of Dec. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

GB Sciences Business Description

Address 9205 W. Russell Road, Suite 240, Las vegas, NV, USA, 89148
GB Sciences Inc is active in the healthcare sector. The company is engaged in developing and utilizing technologies in plant biology, cultivation, and extraction techniques combined with biotechnology, and plans to produce medical-grade cannabis, cannabis concentrates, and cannabinoid therapies. It seeks to be a technology and solution company that converts the cannabis plant into medicines, therapies, and treatments for a range of ailments. The company's intellectual property covers various medical conditions, from which five drug development programs are in the preclinical stage of drug development including its formulations for Parkinson's disease (PD), chronic pain, cytokine release syndrome, depression, and cardiovascular therapeutic programs.